Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis.

By L. Guillevin, C. Pagnoux, A. Karras, C. Khouatra, O. Aumaître, P. Cohen, F. Maurier, O. Decaux, J. Ninet, P. Gobert and 15 more. New England Journal of Medicine, 2014

949 citations recorded by the source corpus.

Subfields: Ophthalmology, Pulmonary and Respiratory Medicine, Rheumatology

View Paper: https://www.semanticscholar.org/paper/c87edc239c131463be10a6c2e8b21e7eabc9f031

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. M. Yates
2. B. Hellmich
3. R. Watts
4. I. Bajema
5. P. Merkel
6. M. Cid
7. Sharon A. Chung
8. B. Crestani

Citations in the corpus

• EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis (2016, methodology): “Renal relapses occurred in 8/17 major relapses in the AZA group and 0/3 in the RTX group (110).”
• 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of ANCA-Associated Vasculitis (2021, positive): “Different doses of rituximab have been used for remission maintenance, including IV 500 mg every 6 months (18) (FDAapproved), IV 1,000 mg every 4 months (20), and IV 1,000 mg every 6 months (21).”